Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NR34
UPID:
MA1C1_HUMAN
Alternative names:
HMIC; Mannosidase alpha class 1C member 1; Processing alpha-1,2-mannosidase IC
Alternative UPACC:
Q9NR34; A6NNE2; B2RNP2; Q9Y545
Background:
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC, also known as HMIC and Mannosidase alpha class 1C member 1, plays a crucial role in the maturation of Asn-linked oligosaccharides. It specifically trims alpha-1,2-linked mannose residues from Man(9)GlcNAc(2) to produce Man(8)GlcNAc(2), then Man(6)GlcNAc, and a small amount of Man(5)GlcNAc. This enzymatic process is vital for proper protein folding and quality control in the endoplasmic reticulum.
Therapeutic significance:
Understanding the role of Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC could open doors to potential therapeutic strategies. Its critical function in protein maturation and quality control suggests that modulating its activity could have implications for diseases related to protein misfolding.